Defining the risks of mesenchymal stromal cell therapy

Darwin J. Prockop; Malcolm Brenner; Willem E. Fibbe; Edwin Horwitz; Katarina Le Blanc; Donald G. Phinney; Paul J. Simmons; Luc Sensebe; Armand Keating

doi:10.3109/14653249.2010.507330

Defining the risks of mesenchymal stromal cell therapy

Darwin J. Prockop, Malcolm Brenner, Willem E. Fibbe, Edwin Horwitz, Katarina Le Blanc, Donald G. Phinney, Paul J. Simmons, Luc Sensebe, Armand Keating

Houston Methodist

Research output: Contribution to journal › Article › peer-review

283 Scopus citations

Abstract

We address the issue of the potential for malignant transformation of cultured mesenchymal stromal cells (MSC) commonly used in clinical cell-therapy protocols and describe the culture conditions under which tumorigenesis is likely to be an extremely uncommon event.

Original language	English (US)
Pages (from-to)	576-578
Number of pages	3
Journal	Cytotherapy
Volume	12
Issue number	5
DOIs	https://doi.org/10.3109/14653249.2010.507330
State	Published - Sep 2010

Keywords

Cell contamination
Mesenchymal stem cells
MSCs

ASJC Scopus subject areas

Immunology
Immunology and Allergy
Molecular Medicine

Access to Document

10.3109/14653249.2010.507330

Cite this

@article{ed251dcc99f44df0bc0c4827016b81b5,

title = "Defining the risks of mesenchymal stromal cell therapy",

abstract = "We address the issue of the potential for malignant transformation of cultured mesenchymal stromal cells (MSC) commonly used in clinical cell-therapy protocols and describe the culture conditions under which tumorigenesis is likely to be an extremely uncommon event.",

keywords = "Cell contamination, Mesenchymal stem cells, MSCs",

author = "Prockop, {Darwin J.} and Malcolm Brenner and Fibbe, {Willem E.} and Edwin Horwitz and {Le Blanc}, Katarina and Phinney, {Donald G.} and Simmons, {Paul J.} and Luc Sensebe and Armand Keating",

year = "2010",

month = sep,

doi = "10.3109/14653249.2010.507330",

language = "English (US)",

volume = "12",

pages = "576--578",

journal = "Cytotherapy",

issn = "1465-3249",

publisher = "Elsevier B.V.",

number = "5",

}

TY - JOUR

T1 - Defining the risks of mesenchymal stromal cell therapy

AU - Prockop, Darwin J.

AU - Brenner, Malcolm

AU - Fibbe, Willem E.

AU - Horwitz, Edwin

AU - Le Blanc, Katarina

AU - Phinney, Donald G.

AU - Simmons, Paul J.

AU - Sensebe, Luc

AU - Keating, Armand

PY - 2010/9

Y1 - 2010/9

N2 - We address the issue of the potential for malignant transformation of cultured mesenchymal stromal cells (MSC) commonly used in clinical cell-therapy protocols and describe the culture conditions under which tumorigenesis is likely to be an extremely uncommon event.

AB - We address the issue of the potential for malignant transformation of cultured mesenchymal stromal cells (MSC) commonly used in clinical cell-therapy protocols and describe the culture conditions under which tumorigenesis is likely to be an extremely uncommon event.

KW - Cell contamination

KW - Mesenchymal stem cells

KW - MSCs

UR - http://www.scopus.com/inward/record.url?scp=77956052070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956052070&partnerID=8YFLogxK

U2 - 10.3109/14653249.2010.507330

DO - 10.3109/14653249.2010.507330

M3 - Article

C2 - 20735162

AN - SCOPUS:77956052070

SN - 1465-3249

VL - 12

SP - 576

EP - 578

JO - Cytotherapy

JF - Cytotherapy

IS - 5

ER -

Defining the risks of mesenchymal stromal cell therapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this